← boardnext 2027-08-30next 2027-12next 2028-11-30
RDPTF
Radiopharm Theranostics, Ltddistress 3/10 · well-funded / low risk$0.010%today-50% from 52w high
Oncology 2
Lead: Colorectal Cancer · est. market ~$12B (approx, global)
Revenue
pre-revenue
Liquidity
$29M
Runway
—
Shares 1y
—
Price & events
-50.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+0.0%
1W
-50.0%
1M
-50.0%
3M
-50.0%
6M
-50.0%
1Y
+1150.0%
2Y
—
5Y
-88.9%
All
Overview
- Market Cap
- $23.65M
- Volume
- 0
- 52 Week Range
- $0.01 – $0.02
- Total Shares
- 2.36B
- Float Shares
- 2.49B
- % Held by Insiders
- 28.09%
- % Held by Institutions
- 11.85%
- Beta
- 0.80
Pipeline stages · 5 programs
LNTH-2403
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
177Lu-BetaBart
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
161Tb RAD402
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
RAD101 (18F-FPIA)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
RAD301 ([68Ga]-RAD301)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 5 trials · 3 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-08-30 Estimated 50% readout ~2027-09-29 | Phase 1 | LNTH-2403 | Imaging, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Non-Small Cell Lung Cancer, Triple Negative Breast Cancer (TNBC) | — | not yet recruiting |
| 2027-12 Estimated 50% readout ~2028-01-15 | Phase 1/2 | 177Lu-BetaBart | Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer, NSCLC (Non-small Cell Lung Cancer), Ovarian Cancer, Cervical Cancer, Endometrial Cancer, TNBC, Triple Negative Breast Cancer, Small Cell Lung Cancer (SCLC ), Head &Amp; Neck Squamous Cell Carcinoma (HNSCC), Esophageal Squamous Cell Carcinoma (ESCC) | — | recruiting |
| 2028-11-30 Estimated 50% readout ~2029-01-14 | Phase 1/2 | 161Tb RAD402 | Castration-resistant Prostate Cancer | — | recruiting |
| 2026-05 | Phase 1 | RAD301 ([68Ga]-RAD301) | Healthy Volunteers, Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Esophageal Squamous Cell Carcinoma, Cervical Cancer, Endometrial Cancer, Ovarian Cancer | 9 | recruiting |
| 2026-04-23 | Phase 2 | RAD101 (18F-FPIA) | Brain Metastases From Solid Tumors | 30 | active not recruiting |
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors — Colorectal Cancer
- ABBVAbbVie Inc.$451.1B · D2
- NVSEFNOVARTIS AG$292.0B · D3
- RVMDRevolution Medicines, Inc.$40.3B · D1
- BNTXBioNTech SE$23.1B · D1
- SMMTSummit Therapeutics Inc.$11.6B · D3
- IDYAIDEAYA Biosciences, Inc.$3.0B · D3
- VSTMVerastem, Inc.$515M · D5
- CRDFCardiff Oncology, Inc.$59M · D3
- CNTXContext Therapeutics Inc.$57M · D2
- AZNASTRAZENECA PLC— · D3
Recent news
- 2026-07-22Radiopharm Theranostics (NASDAQ: RADX) reports strong RAD204 and RAD101 trial results - Stock Titan
- 2026-07-22Radiopharm's brain-metastasis scan showed 93% MRI concordance - Stock Titan
- 2026-07-22Health Check: Radiopharm goes to the well for $16 million after clinical trial double delight - Stockhead
- 2026-07-21Radiopharm Theranostics reports 93% trial success - grafa.com
- 2026-07-06A$5,885,131 R&D tax refund supports Radiopharm Theranostics (Nasdaq: RADX) - Stock Titan
- 2026-06-30Theranostics (NASDAQ: RADX) reports option lapses and new RADAN grants - Stock Titan
- 2026-04-23Radiopharm Theranostics Reports Business Update - Moomoo
- 2026-04-08Radiopharm (ASX:RAD) Advances RAD202 Trial Following Positive Safety Review - Kalkine
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.